Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

Comparison of clinical outcomes in adamantinomatous and papillary craniopharyngioma: a baseline analysis before the targeted therapy era
Juncker, Ryan B. , Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Zada, Gabriel, Kshettry, Varun R., BENJAMIN, CAROLINA, Gompel, Jamie J. Van, Catalino, Michael, Mamelak, Adam, Zwagerman, Nathan, Little, Andrew S., Gardner, Paul, Karsy, Michael, Couldwell, William T., Rennert, Robert C., Palmer, Joshua D., Prevedello, Daniel M., Wu, Kyle C., Karsy, Michael , Barkhoudarian, Garni , Van Gompel, Jamie, Karsy, Michael , Damante, Mark A. , Kim, Albert H , Evans, James J., Fernandez‐Miranda, Juan C. , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Gompel, Jamie J. Van , Catalino, Michael P. , Mamelak, Adam N. , Zwagerman, Nathan T. , Little, Andrew S. , Pacult, Mark A. , Couldwell, William T. , Rennert, Robert C , Palmer, Joshua D. , Prevedello, Daniel M.

Mayo Clinic

Neurosurgical Focus | May 27, 2026 | Volume: 60 | Issue: 6 | Pages: E11

10.3171/2026.2.focus251172 | PMID 42224722 Get It

OBJECTIVE Historically, craniopharyngioma (CP) was divided into adamantinomatous CP (ACP) and papillary CP (PCP) subtypes based on histopathological features. However, each harbors a unique genetic profile and progressively differing treatment paradigms, leading to their reclassification by the WHO in 2016 as two distinct entities. Descriptive in nature, this large multi-institutional study aimed to establish current differences between the presentation, treatment patterns, and clinical course of these pathologies to serve as a baseline for future studies as new treatment paradigms emerge. METHODS The authors queried the Registry for Adenomas of the Pituitary and Related Disorders (RAPID) database, which encompassed patients from 14 participating institutions across the United States between 2000 and 2024. The database was screened for adult patients who underwent initial CP treatment with a confirmed histopathological diagnosis of ACP or PCP. Patient demographic characteristics, clinical course, tumor treatment, and outcomes data were collected and compared by CP type. RESULTS The final analysis included 273 ACP and 99 PCP adult patients who underwent initial surgical treatment. ACP patients presented younger on average (mean 48.3 vs 52.8 years, p = 0.034). PCP patients were more likely to present with hypothyroidism (33.3% vs 20.5%, p = 0.010), hyperlipidemia (25.3% vs 15.8%, p = 0.036), fatigue (28.3% vs 17.6%, p = 0.024), temperature intolerance (9.1% vs 1.5%, p < 0.001), and cardiac arrhythmia (6.1% vs 1.1%, p = 0.006). The groups demonstrated similar postsurgical and neuroendocrinological outcomes. Postoperative median (IQR) progression-free survival did not significantly differ between groups (19.0 [7.0–37.0] for ACP vs 5.0 [3.5–7.5] months for PCP, p = 0.972). ACP patients were more likely to receive radiation after surgery (27.8% vs 15.2%, p = 0.012). CONCLUSIONS This large multicenter descriptive study aimed to characterize similarities and differences between the clinical courses of molecularly distinct ACP and PCP, which has not previously been described. The findings should serve as a baseline to inform future studies, particularly with the recent introduction of targeted therapy for PCP.
Frailty and postoperative outcomes following craniopharyngioma resection: a multicenter Registry for Adenomas of the Pituitary and Related Disorders analysis
Chen, Anthony Yulin, Feng, Rui, Collopy, Calen, Rennert, Robert C., Couldwell, William T., Kshettry, Varun R., Gardner, Paul, Silverstein, Julie M., Kim, Albert H., Barkhoudarian, Garni, Kelly, Daniel, Pacione, Donato , Suryadevara, Carter M. , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Wu, Kyle C., Prevedello, Daniel M., BENJAMIN, CAROLINA, Catalino, Michael P., Mamelak, Adam, Cheok, Stephanie K., Zwagerman, Nathan T., Gompel, Jamie J. Van, Fernandez-Miranda, Juan C., Yuen, Kevin C. J., Little, Andrew S., Karsy, Michael, Evans, James J., Karsy, Michael , Barkhoudarian, Garni , Palit, Sandhya R. , Karsy, Michael , Kelleher, Sean T., Rennert, Robert C , Couldwell, William T. , Kshettry, Varun R. , Silverstein, Julie , Kim, Albert H , Kelly, Daniel, Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Prevedello, Daniel M. , Catalino, Michael Paul, Mamelak, Adam N. , Cheok, Stephanie , Zwagerman, Nathan T. , Gompel, Jamie J. Van , Fernandez‐Miranda, Juan C. , Yuen, Kevin C.J. , Little, Andrew S. , Evans, James J.

Mayo Clinic

Neurosurgical Focus | May 27, 2026 | Volume: 60 | Issue: 6 | Pages: E7

10.3171/2026.2.focus251160 | PMID 42224740 Get It

OBJECTIVE Frailty is a known predictor of adverse outcomes in pituitary surgery, yet its impact regarding craniopharyngioma remains unclear. The authors assessed preoperative frailty, measured by the 11-factor modified frailty index (mFI-11), and its association with perioperative morbidity among adult patients undergoing craniopharyngioma surgery. METHODS Using the Registry for Adenomas of the Pituitary and Related Disorders (RAPID) database, the authors performed a retrospective cohort study of the records of patients ≥ 18 years of age who underwent craniopharyngioma surgery between June 2007 and November 2024. Patients were stratified into the following categories according to their numeric mFI-11 score: fit (scores 0 and 1), managing well (scores 2 and 3), and mildly frail (scores 4–6). Primary outcomes included hospital length of stay (LOS) and discharge disposition. Secondary outcomes included 90-day readmission, surgical outcomes, and complications. Multivariable analyses were performed to identify independent predictors of hospital LOS and non-home discharge, adjusting for age, surgeon experience, American Society of Anesthesiologists class, complications, and surgical approach. RESULTS Among 278 patients (221 fit, 43 managing well, 14 mildly frail), higher-frailty patients were older (mean age 47.8 ± 16.1 years in fit vs 60.1 ± 12.5 years in managing well vs 67.6 ± 8 years in mildly frail, p < 0.001) and more likely to present urgently (24.2% vs 36.4% vs 78.6%, p = 0.001). Gross-total resection was achieved less frequently in frail patients (44.8% vs 24.3% vs 23.1%, p = 0.030). Overall complication rates were similar; however, increasing frailty was associated with higher rates of postoperative mortality (0% vs 2.8% [1/36] vs 7.7% [1/13], p = 0.018), pneumonia (0.5% [1/195] vs 2.8% [1/36] vs 15.4% [2/13], p = 0.006), and reintubation (2.6% [5/195] vs 2.8% [1/36] vs 30.8% [4/13], p = 0.002). Higher frailty was associated with a stepwise rise in median [IQR] LOS (5 [3–8] days vs 7 [4–12] days vs 13 [6.5–21.8] days, p < 0.001) and remained an independent predictor of extended LOS on multivariable analysis (β = 1.729 per point, p = 0.006). Rates of non-home discharge showed a similar pattern (9.2% vs 30.0% vs 64.3%, p < 0.001), with frailty independently predicting non-home discharge (OR 2.352, 95% CI 1.527–3.822). Unplanned 90-day readmission rates were significantly higher in the mildly frail cohorts (22.5% vs 45.7% vs 53.8%, p = 0.002). CONCLUSIONS The mFI-11 scores independently predicted perioperative morbidity following craniopharyngioma resection. Incorporating frailty screening into preoperative screening may improve risk stratification, family and patient counseling, and discharge planning.
Predictors of hospital length of stay, discharge disposition, and readmission after craniopharyngioma surgery: a multicenter study from the RAPID database
Tenhoeve, Samuel A. , Tang, Anthony , Orton, Cody , Gautam, Diwas, Abdul-Rahman, Nana-Hawwa, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Kshettry, Varun R., Wu, Kyle C., Benjamin, Carolina G., Gompel, Jamie J. Van, Catalino, Michael P., Mamelak, Adam N., Zwagerman, Nathan T., Cheok, Stephanie K., Little, Andrew S., Zenonos, Georgios A., Karsy, Michael, Morshed, Ramin A., Blackburn, Spiros L., Mukherjee, Debraj, Beer-Furlan, Andre, Couldwell, William T., Gardner, Paul A., Rennert, Robert C., Karsy, Michael , Mukherjee, Debraj , Barkhoudarian, Garni , Van Gompel, Jamie, Palit, Sandhya R. , Mukherjee, Debraj , Karsy, Michael , Gautam, Diwas , Abdul‐Rahman, Nana‐Hawwa , Silverstein, Julie , Kim, Albert H , Evans, James J., Fernandez‐Miranda, Juan C. , Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Gompel, Jamie J. Van , Catalino, Michael Paul, Mamelak, Adam N, Zwagerman, Nathan T. , Cheok, Stephanie , Little, Andrew S. , Zenonos, Georgios A. , Morshed, Ramin A. , Blackburn, Spiros L., Beer‐Furlan, André , Couldwell, William T. , Gardner, Paul A. , Rennert, Robert C

Mayo Clinic

Neurosurgical Focus | May 27, 2026 | Volume: 60 | Issue: 6 | Pages: E6

10.3171/2026.2.focus251047 | PMID 42224727 Get It

OBJECTIVE Craniopharyngiomas are benign intracranial tumors that can be difficult to manage operatively and often result in postoperative complications and prolonged recovery. Understanding the factors that influence length of stay (LOS), discharge disposition, and readmission can guide perioperative planning and patient counseling. The authors examined the clinical, radiographic, and surgical predictors of extended LOS (eLOS), nonhome discharge, 90-day readmission, and hospitalization ratio (HR) after craniopharyngioma resection using a large, multicenter cohort. METHODS A retrospective analysis was conducted using the Registry of Adenomas of the Pituitary and Related Disorders database, encompassing 469 patients who underwent craniopharyngioma resection at 14 US academic centers from 2011 to 2025. Patients were stratified by 4 outcomes: eLOS (> 75th percentile), discharge to home versus skilled nursing facility/rehabilitation, 90-day hospital readmission, and hospitalization ratio (i.e., integration of initial and readmission LOS). Multivariable logistic regression models identified independent predictors for each outcome among patient and surgical variables. RESULTS An eLOS (> 10 days) was independently associated with preoperative memory loss (OR 3.75, 95% CI 1.95–7.21), gait imbalance (OR 5.90, 95% CI 1.53–22.70), and postoperative complications (OR 4.07, 95% CI 2.34–7.06). The use of a nasoseptal flap was protective against an eLOS (OR 0.52, 95% CI 0.28–0.93). Discharge to home was predicted by an endoscopic approach (OR 3.87, 95% CI 1.78–8.44) and postoperative intact thirst (OR 2.22, 95% CI 1.05–4.66) and negatively predicted by preoperative diabetes mellitus (OR 0.21, 95% CI 0.09–0.50), LOS (OR 0.87, 95% CI 0.84–0.91), and postoperative cognitive dysfunction (OR 0.30, 95% CI 0.13–0.72). Among 385 patients with follow-up data, a 90-day readmission was independently associated with postoperative complications (OR 5.62, 95% CI 3.12–10.13), preexisting coronary artery disease (OR 4.30, 95% CI 1.46–12.69), and postoperative cognitive dysfunction (OR 3.33, 95% CI 1.76–6.44). A higher HR was associated with diabetes mellitus (unstandardized B 0.059, 95% CI 0.010–0.108, p = 0.02), postoperative complications (unstandardized B 0.054, 95% CI 0.021–0.086, p = 0.001), and postoperative cognitive dysfunction (unstandardized B 0.049, 95% CI 0.006–0.092, p = 0.02). Tumor pathologic subtype and size, prior treatment, extent of resection, and surgeon experience were not directly predictive of outcomes. CONCLUSIONS Cognitive and functional status, systemic comorbidities, and postoperative complications, in addition to surgical approach, are important predictors of the early clinical course after craniopharyngioma surgery. Early identification of high-risk patients may help to guide treatment decisions, improve discharge planning, and reduce healthcare utilization.
Source‐free domain adaptation for multi‐institutional chest X‐ray images
Kim, Hyoyi , Lee, Seoyoung, Cho, S, Cho, Seungryong

Mayo Clinic

Journal of Applied Clinical Medical Physics | May 23, 2026 | Volume: 27 | Issue: 5 | Pages: No page available

10.1002/acm2.70626 | PMID 42176315 Get It

Abstract Background Machine learning models for chest X‐ray (CXR)‐based tuberculosis (TB) detection often suffer from performance drops when deployed across institutions due to domain shifts caused by differences in patient populations, imaging protocols, and equipment. Domain adaptation has been widely studied to address the problem, but privacy regulations restrict data sharing, making conventional approaches infeasible. Purpose We aim to enhance TB detection performance when a detector model is shared across multiple clinical sites without accessing any source data or statistics. This problem is related to source‐free domain adaptation (SFDA) but requires special designs for imbalanced binary classification. Methods We propose two methods for TB detection, which are based on Source HypOthesis Transfer (SHOT) and SFDA via source Distribution Estimation (SFDA‐DE), respectively. As the main ideas of our methods, we propose ranking‐based pseudo‐labeling and selective fine‐tuning of network layers to address severe class imbalance and prevent overfitting. Results On six unseen target domains with high class imbalance, our proposed SFDA methods significantly improved the average F1 score and AUROC compared to non‐adapted models, all without accessing source data during adaptation. Conclusions Our methods offer a privacy‐preserving and effective strategy to improve the generalization of TB detection models across institutions, addressing domain shifts while complying with data‐sharing restrictions.
Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies
Morganti, Stefania , Kim, Se Eun , Jin, Qingchun , Cha, Jaeyoon , Zeigler, Jacqueline E, Newman, Alexandra Bili, Kirkner, Gregory J. , Snow, Craig , Zheng, Yue, Vincuilla, Julie, Parker, Tonia , Buehler, Ryan M. , Bychkovsky, Brittany L , Dibble, Kate E. , Sella, Tal , Ruddy, Kathryn J, Rosenberg, Shoshana M, Collins, Laura C. , Peppercorn, Jeffrey, Schapira, Lidia, Guzman-Arocho, Yaileen D, Come, Steven E. , Warner, Ellen, Poorvu, Philip D. , Lambertini, Matteo, Curigliano, G, Hughes, Melissa E. , Mittendorf, Elizabeth A, King, Tari A, Lin, Nancy U, Garber, Judy E, Tayob, Nabihah, Tolaney, S M, Partridge, Ann H, Zheng, Yue , Newman, Alexandra B , Zheng, Yue , Ruddy, Kathryn J , Peppercorn, Jeffrey M , Borges, Virginia F , Guzman-Arocho, Yaileen D , Come, Steven , Poorvu, Philip D , Lambertini, Matteo , Curigliano, Giuseppe , Mittendorf, EA , King, Tari A , Lin, Nancy U , Garber, J. E. , Tayob, Nabihah , Tolaney, Sara , Partridge, Ann H , Lynce, Filipa , Kirkner, Gregory , Snow, Craig , Vincuilla, Julie, Ruddy, Kathryn J. , Rosenberg, Shoshana M. , Peppercorn, Jeffrey , Schapira, Lidia , Borges, Virginia F. , Guzmán‐Arocho, Yaileen D. , Warner, Ellen , Lambertini, Matteo , Curigliano, Giuseppe , King, Tari A. , Lin, Nancy U. , Garber, Judy E. , Partridge, Ann H.

Mayo Clinic

JNCI Cancer Spectrum | May 23, 2026 | Volume: 10 | Issue: 4 | Pages: No page available

10.1093/jncics/pkag055 | PMID 42185079 Get It

Abstract Background Whether outcomes of germline BRCA1/2 (gBRCA1/2)-associated breast cancer differ compared with sporadic tumors is controversial. We explored the impact of gBRCA1/2 pathogenic variant (PV) status beyond established prognostic features. Methods We conducted 2 retrospective, matched cohort studies comparing gBRCA1/2 PV carriers and noncarriers with HER2-negative, stage I-III breast cancer (Clinical Outcomes Quality Database [COQD] cohort: 185 carriers, 555 noncarriers; Young Women’s Breast Cancer Study [YWS] cohort: 113 carriers, 226 noncarriers). Matching factors were age, stage, hormone receptor status, and year of diagnosis. Clinicopathological features, treatments, and survival outcomes were compared between carriers and noncarriers. Results Most patients in COQD had stage I-II disease (87.2%), and more carriers than noncarriers had genetic testing before diagnosis (33% vs 5.6%, P &lt; .001). In YWS, 22.7% of patients had stage III tumors, and few were tested before diagnosis (14.8% of carriers vs 1.7% of noncarriers; P &lt; .001). Carriers in COQD received chemotherapy more often than noncarriers (81.1 vs 67.0%, P &lt; .001), including platinum (P = .010); the proportion was similar for carriers and noncarriers in YWS. After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts. Triple-negative tumors appeared to drive the differences. Conclusions We observed a trend toward improved outcomes in gBRCA1/2 PV carriers compared with noncarriers. These findings suggest that carriers should not receive more aggressive treatment solely based on their germline mutation status. Prospective clinical trials in this population are warranted.
Validation of MELD 3.0 in 2 centers from different continents
Duong, Nikki, Huynh, Daniel J. , Kim, W. Ray, Shah, Neil , Biggins, Scott W. , Kwong, Allison, Kwong, Allison J. , Duong, Nikki , Kwong, Allison , Nikzad, Newsha , Shah, Neil

Mayo Clinic

Hepatology Communications | May 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1097/hc9.0000000000000958 | PMID 42172502 Get It

Landscape of reversion alterations in homologous recombination genes reveals evolutionary constraints
Decker, Brennan, Sisoudiya, Saumya D. , Thornton, James, Cui, Chenming, Solieva, Shahlo , Shi, Tao, Guintini, Fabio, Fleischmann, Zoe, Hartman, Mark, Bailey, Shannon T., Leibowitz, Jeffrey , Sokol, Ethan S, Schrock, Alexa B. , Couch, Fergus J, Reiss, Kim A, Domchek, Susan M, Sivakumar, Smruthy, Decker, Brennan , Cui, Chenming , Harada, Taku, Madison, Russell W. , Datta, Arindam , Fleischmann, Zoe , Frampton, Garrett M. , Couch, Fergus J. , Reiss, Kim A. , Domchek, Susan M. , Bowman, Gregory R. , Greenberg, Roger A. , Nathanson, Katherine L.

Mayo Clinic

No container title available | May 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.19.726319 Get It

ABSTRACT Reversion mutations (REVs) restore homologous recombination repair (HRR) and confer resistance to PARP inhibitors (PARPi) in HR-deficient cancers. Yet, their prevalence, mechanisms, and biological constraints remain undefined. We analyzed genomic profiling of 609,464 tissue and liquid biopsy samples across multiple cancer types to delineate the pan-cancer landscape of REVs. REVs were identified in eight HRR genes, most frequently BRCA2 and BRCA1 and notably never in ATM or CHEK2 . REVs exclusively impacted truncating pathogenic variants, predominantly through large in-frame and exon-level deletions, associated with repetitive sequences. Conserved functional domains are relatively depleted of REVs. Structural modeling and functional studies support that exon-level deletions preserve critical domain architecture and confer PARPi resistance. The study establishes HRR reversion as a structurally permissive, yet evolutionarily constrained, resistance mechanism with implications on response, monitoring, and therapeutic strategy. One Sentence Summary Homologous recombination reversion evolves through structurally tolerated, microhomology-driven alterations that restore DNA repair under therapeutic selection across cancers.
Successful pocket creation method using a multimodal device in endoscopic submucosal dissection for a colonic lateral spreading tumor
Esaki, Mitsuru , Fukami, Norio, Yamaguchi, Daisuke , Hassan, Ibrahim H., KIM, H, Jue, Terry L., Fukami, Norio , Fukami, Norio , Kim, Hyun Jae, Esaki, Mitsuru

Mayo Clinic

Endoscopy | May 20, 2026 | Volume: 58 | Issue: S 02 | Pages: E611-E612

10.1055/a-2852-7351 | PMID 42161281 Get It

Amelanotic Melanoma is Associated With Higher Rates of Metastasis at Presentation and Disease-specific Death: A National Cancer Registry Study
Yoon, Jeesoo , Brewer, Jerry D., Vidal, Nahid Y. , Kim, Yong-Hun , Brewer, Jerry D.

Mayo Clinic

Dermatologic Surgery | May 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005185 Get It

Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma
Kessel, Adam , Kim, H, Brown, P D, Lehrer, Eric J. , Laack, N., Mahajan, Anita, Yan, Elizabeth, Schultz, Sydney E., Kizilbash, Dr Sani, Neth, Bryan, Sener, Ugur, Waddle, Mark, Breen, William G. , Kowalchuk, Roman O. , Neth, Bryan J. , Kessel, Adam C , Brown, Paul D , Kizilbash, Sani, Neth, Byran J. , Sener, Ugur , Waddle, Mark R , Mahajan, Anita, Kizilbash, Sani H. , Sener, Uğur

Mayo Clinic

Cancer | May 20, 2026 | Volume: 132 | Issue: 11 | Pages: No page available

10.1002/cncr.70463 | PMID 42159181 Get It

Abstract Background Vorasidenib is Food and Drug Administration‐approved for treatment of grade 2 isocitrate dehydrogenase (IDH)–mutant gliomas and has demonstrated a benefit in progression‐free survival compared to a placebo. This study assessed the cost‐effectiveness of this treatment strategy compared to standard treatment: observation or chemoradiation (CRT). Methods The authors used an integrated Markov model to compare quality‐adjusted life‐years (QALY) gained and cost‐effectiveness of patients with IDH‐mutated low‐grade glioma (LGG) treated with vorasidenib, observation, or CRT. Outcomes were expressed as incremental cost‐effectiveness ratios (ICERs) per QALY gained. Treatment is considered cost‐effective if it meets the commonly accepted willingness‐to‐pay threshold of $100,000 per QALY gained. Results Based on model parameters, vorasidenib demonstrated an ICER of $356,756 per QALY when compared to CRT. When compared to observation, vorasidenib demonstrated an improved ICER of $215,191 per QALY. On one‐way sensitivity analysis compared to observation, median cost of vorasidenib and median overall survival were most likely to affect ICER with only marginal changes on analysis of other model factors. For ICER to become ≤$100,000 compared to observation, the cost of vorasidenib would need to drop to below $14,072 monthly or have a median survival gain of at least 11.9 years. The probabilistic sensitivity analysis demonstrated that vorasidenib was favored in none of 5000 Monte Carlo iterations. Conclusion Using the best available data, the current price of vorasidenib does not meet commonly accepted cost‐effectiveness thresholds in treatment of IDH‐mutated LGGs.